When Bruce Springsteen abruptly postponed his two Philadelphia concerts at Citizens Bank Park in August ― and then went on to play five shows in New England and New Jersey before calling off the rest of his 2023 dates ― ...
Nov 13, 2023
0
0
Roberto Saldana was 16 when he developed severe stomach pain and diarrhea, but two more years would pass before he was diagnosed with inflammatory bowel disease, or IBD.
Nov 9, 2023
0
3
The U.S. Food and Drug Administration has approved Amgen's Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.
Nov 3, 2023
0
1
The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this chronic and debilitating ...
Oct 30, 2023
0
0
Inflammatory bowel diseases (IBDs), such as Crohn's disease or ulcerative colitis, arise when there is a dysregulation of the cell signaling pathways controlling the maintenance of homeostasis in the gut, leading to a chronic ...
Oct 26, 2023
0
0
The lung is one of the tissues most sensitive to radiation in the human body. People exposed to high radiation doses following nuclear incidents develop radiation-induced lung injury (RILI), which affects the function of ...
Oct 17, 2023
0
22
Inflammatory breast cancer is rare, but it's aggressive, fast-growing and hard to detect early, so it's important to know the warning signs.
Oct 16, 2023
0
1
Some common medications—including antidepressants, sleep aids and painkillers—may dull the driving skills of seniors, a new study finds.
Oct 3, 2023
0
80
Millions of Americans suffer from arthritis, and many reach for medication to ease their joint pain and inflammation.
Sep 19, 2023
0
1
A preclinical study led by Monash University has discovered a drug combination with the potential to treat one of the most fatal and globally widespread cancers, a type of primary liver cancer called hepatocellular carcinoma ...
Sep 14, 2023
0
34
